Understanding how COP1 affects prostate cancer growth and treatment resistance
COP1 REGULATION OF AR SIGNALING AND PROSTATE CANCER GROWTH AND THERAPY RESISTANCE
This study is looking at how a protein called COP1 affects another protein, GATA2, which is important in prostate cancer growth and treatment resistance, to see if targeting COP1 could help improve treatment options for patients with advanced prostate cancer that doesn't respond to standard therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11078304 on NIH RePORTER |
What this research studies
This research investigates the role of COP1, an E3 ubiquitin ligase, in regulating GATA2, a protein that influences prostate cancer growth and resistance to therapies. By promoting the degradation of GATA2, COP1 may inhibit androgen receptor signaling and improve responses to treatments like docetaxel in patients with advanced prostate cancer. The study aims to uncover the molecular mechanisms behind COP1's action and its potential as a therapeutic target for patients with castration-resistant prostate cancer. Patients may benefit from insights that could lead to new treatment strategies for resistant forms of prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with castration-resistant prostate cancer who have not responded to standard therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve treatment outcomes for patients with advanced prostate cancer.
How similar studies have performed: Other research has shown promising results in targeting similar pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Yang, Feng — Baylor College of Medicine
- Study coordinator: Yang, Feng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.